Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 phase 3 study in adults with amyotrophic lateral sclerosis
NL-OMON58629Phase 3Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoint: Change from baseline in ALSFRS-R total score at Week 48 adjusting for mortality. Started Dec 2021; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON58629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58629.